Clene Inc.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.63
- Today's High:
- $0.675
- Open Price:
- $0.6653
- 52W Low:
- $0.85
- 52W High:
- $5.13
- Prev. Close:
- $0.66
- Volume:
- 311030
Company Statistics
- Market Cap.:
- $81.53 million
- Book Value:
- -0.021
- Revenue TTM:
- $550000
- Operating Margin TTM:
- -8328.18%
- Gross Profit TTM:
- $447000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -61.4%
- Return on Equity TTM:
- -14530.26%
Company Profile
Clene Inc. had its IPO on 2020-12-31 under the ticker symbol CLNN.
The company operates in the Healthcare sector and Biotechnology industry. Clene Inc. has a staff strength of 75 employees.
Stock update
Shares of Clene Inc. opened at $0.67 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.63 - $0.68, and closed at $0.63.
This is a -4.39% slip from the previous day's closing price.
A total volume of 311,030 shares were traded at the close of the day’s session.
In the last one week, shares of Clene Inc. have slipped by -13.56%.
Clene Inc.'s Key Ratios
Clene Inc. has a market cap of $81.53 million, indicating a price to book ratio of 108.1979 and a price to sales ratio of 187.0781.
In the last 12-months Clene Inc.’s revenue was $550000 with a gross profit of $447000 and an EBITDA of $-44579000. The EBITDA ratio measures Clene Inc.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Clene Inc.’s operating margin was -8328.18% while its return on assets stood at -61.4% with a return of equity of -14530.26%.
In Q1, Clene Inc.’s quarterly earnings growth was a positive 61.4% while revenue growth was a positive 256.7%.
Clene Inc.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.4 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Clene Inc.’s profitability.
Clene Inc. stock is trading at a EV to sales ratio of 204.4827 and a EV to EBITDA ratio of -4.2737. Its price to sales ratio in the trailing 12-months stood at 187.0781.
Clene Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $39.89 million
- Total Liabilities
- $16.88 million
- Operating Cash Flow
- $4.72 million
- Capital Expenditure
- $278000
- Dividend Payout Ratio
- 0%
Clene Inc. ended 2024 with $39.89 million in total assets and $0 in total liabilities. Its intangible assets were valued at $39.89 million while shareholder equity stood at $-1627000.00.
Clene Inc. ended 2024 with $0 in deferred long-term liabilities, $16.88 million in other current liabilities, 8000.00 in common stock, $-204989000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $18.44 million and cash and short-term investments were $18.44 million. The company’s total short-term debt was $10,335,000 while long-term debt stood at $16.62 million.
Clene Inc.’s total current assets stands at $24.82 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $3.11 million compared to accounts payable of $608000.00 and inventory worth $88000.00.
In 2024, Clene Inc.'s operating cash flow was $4.72 million while its capital expenditure stood at $278000.
Comparatively, Clene Inc. paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.63
- 52-Week High
- $5.13
- 52-Week Low
- $0.85
- Analyst Target Price
- $8.43
Clene Inc. stock is currently trading at $0.63 per share. It touched a 52-week high of $5.13 and a 52-week low of $5.13. Analysts tracking the stock have a 12-month average target price of $8.43.
Its 50-day moving average was $0.74 and 200-day moving average was $1.02 The short ratio stood at 15.84 indicating a short percent outstanding of 0%.
Around 6420% of the company’s stock are held by insiders while 413% are held by institutions.
Frequently Asked Questions About Clene Inc.
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases. The company’s products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.